Difference between revisions of "Template:Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative"

From blackwiki
Jump to navigation Jump to search
imported>Medgirl131
(Undid revision 911141042 by 31.49.34.42 (talk) -- This is inserting extra line breaks in articles.)
imported>Medgirl131
Line 1: Line 1:
 
<center>
 
<center>
 
{| class="wikitable sortable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}"
 
{| class="wikitable sortable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}"
|+ class="nowrap" | {{Navbar|Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative|mini=y}} Health risks in the {{abbr|CEEs|conjugated estrogens}}/{{abbr|MPA|medroxyprogesterone acetate}} substudy of the Women's Health Initiative
+
|+ class="nowrap" | {{Navbar|Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative|mini=y}} Health risks in the {{No selflink|conjugated estrogens/medroxyprogesterone acetate}} substudy of the Women's Health Initiative
 
|-
 
|-
! rowspan="2" | Event !! rowspan="2" style="width: 205px;" | Relative Risk {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}} vs. placebo at 5.2 years (95% {{abbr|CI|confidence interval}}{{NoteTag|Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.}}) !! style="width: 75px;" data-sort-type="number" | Placebo<br />(n = 8102) !! style="width: 75px;" data-sort-type="number" | {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}}<br />(n = 8506)
+
! rowspan="2" | Event !! rowspan="2" style="width: 205px;" | {{Abbr|RR|Relative risk}} of {{Abbr|CEEs|Conjugated estrogens}}/{{Abbr|MPA|Medroxyprogesterone acetate}} vs. placebo at 5.2 years (95% {{Abbr|CI|confidence interval}}){{Efn|Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.}} !! style="width: 75px;" data-sort-type="number" | Placebo<br />(n = 8,102) !! style="width: 75px;" data-sort-type="number" | {{Abbr|CEEs|Conjugated estrogens}}/{{Abbr|MPA|Medroxyprogesterone acetate}}<br />(n = 8,506)
 
|-
 
|-
! colspan="2" | Absolute Risk per 10,000 Women-Years
+
! colspan="2" | Absolute risk per 10,000 woman-years
 
|-
 
|-
| [[Coronary heart disease]] events<br />({{dfn|non-fatal [[myocardial infarction]]}}, {{dfn|death|Coronary heart disease death|}}) || 1.29 (1.02–1.63)<br />1.32 (1.02–1.72)<br />1.18 (0.70–1.97) || 30<br />23<br />6 || 37<br />30<br />7
+
| [[Coronary heart disease]] events{{Efn|Non-fatal [[myocardial infarction]].}}{{Efn|Coronary heart disease death.}} || 1.29 (1.02–1.63)<br />1.32 (1.02–1.72)<br />1.18 (0.70–1.97) || 30<br />23<br />6 || 37<br />30<br />7
 
|-
 
|-
| [[Invasive breast cancer]]{{efn|Includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer.}} || 1.26 (1.00–1.59) || 30 || 38
+
| [[Invasive breast cancer]]{{Efn|Includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer.}} || 1.26 (1.00–1.59) || 30 || 38
 
|-
 
|-
 
| [[Stroke]] || 1.41 (1.07–1.85) || 21 || 29
 
| [[Stroke]] || 1.41 (1.07–1.85) || 21 || 29
Line 23: Line 23:
 
| Death due to causes other than above || 0.92 (0.74–1.14) || 40 || 37
 
| Death due to causes other than above || 0.92 (0.74–1.14) || 40 || 37
 
|-
 
|-
| Global Index{{efn|A subset of the events was combined in a "global index", defined as the earliest occurrence of coronary heart disease events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes.}} || 1.15 (1.03–1.28) || 151 || 170
+
| Global Index{{Efn|A subset of the events was combined in a "global index", defined as the earliest occurrence of coronary heart disease events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes.}} || 1.15 (1.03–1.28) || 151 || 170
 
|-
 
|-
| [[Deep vein thrombosis]]{{efn|name=not-gi|Not included in Global Index.}} || 2.07 (1.49–2.87) || 13 || 26
+
| [[Deep vein thrombosis]]{{Efn|name=not-gi|Not included in Global Index.}} || 2.07 (1.49–2.87) || 13 || 26
 
|-
 
|-
| [[Vertebral fracture]]s{{efn|name=not-gi}} || 0.66 (0.44–0.98) || 15 || 9
+
| [[Vertebral fracture]]s{{Efn|name=not-gi}} || 0.66 (0.44–0.98) || 15 || 9
 
|-
 
|-
| Other [[osteoporotic fracture]]s{{efn|name=not-gi}} || 0.77 (0.69–0.86) || 170 || 131
+
| Other [[osteoporotic fracture]]s{{Efn|name=not-gi}} || 0.77 (0.69–0.86) || 170 || 131
 
|- class="sortbottom"
 
|- class="sortbottom"
| colspan="10" style="background-color:#eaecf0; text-align: center;" | '''Sources:''' <noinclude><ref name="EstraceLabel">{{cite web | url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/081295s014,084499s042,084500s044lbl.pdf | title=ESTRACE TABLETS, (estradiol tablets, USP) | author=Warner Chilcott | authorlink=Warner Chilcott | date=March 2005 | publisher=fda.gov | format=PDF | accessdate=27 November 2016 }}</ref><ref name="pmid12117397">{{cite journal | vauthors = Rossouw JE, Anderson GL, [[Ross Prentice|Prentice RL]], LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J | title = Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | journal = JAMA | volume = 288 | issue = 3 | pages = 321–33 | date = July 2002 | pmid = 12117397 | doi = 10.1001/jama.288.3.321 | url = }}</ref></noinclude><includeonly>See template.</includeonly>
+
 
 +
| colspan="10" style="width: 1px; background-color:#eaecf0; text-align: center;" | {{Hidden | <noinclude>expanded = true |</noinclude> header = Footnotes and sources | content = '''Footnotes:''' {{Notelist}}
 +
 
 +
'''Sources:''' <noinclude><ref name="EstraceLabel">{{cite web | url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/081295s014,084499s042,084500s044lbl.pdf | title=ESTRACE TABLETS, (estradiol tablets, USP) | author=Warner Chilcott | authorlink=Warner Chilcott | date=March 2005 | publisher=fda.gov | format=PDF | accessdate=27 November 2016 }}</ref><ref name="pmid12117397">{{cite journal | vauthors = Rossouw JE, Anderson GL, [[Ross Prentice|Prentice RL]], LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J | title = Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | journal = JAMA | volume = 288 | issue = 3 | pages = 321–33 | date = July 2002 | pmid = 12117397 | doi = 10.1001/jama.288.3.321 | url = }}</ref></noinclude><includeonly>See template.</includeonly>}}
 
|}
 
|}
 
</center><!--
 
</center><!--
Line 37: Line 40:
 
--><noinclude>{{Documentation|content=
 
--><noinclude>{{Documentation|content=
 
{{Improve documentation|date=March 2019}}
 
{{Improve documentation|date=March 2019}}
==Notes and references==
+
==References==
{{Notelist}}
 
{{Notefoot}}
 
 
{{Reflist}}
 
{{Reflist}}
 
}}
 
}}

Revision as of 06:06, 26 December 2019

Health risks in the Template:No selflink substudy of the Women's Health Initiative

Event RR of CEEs/MPA vs. placebo at 5.2 years (95% CI)[lower-alpha 1] Placebo
(n = 8,102)
CEEs/MPA
(n = 8,506)
Absolute risk per 10,000 woman-years
Coronary heart disease events[lower-alpha 2][lower-alpha 3] 1.29 (1.02–1.63)
1.32 (1.02–1.72)
1.18 (0.70–1.97)
30
23
6
37
30
7
Invasive breast cancer[lower-alpha 4] 1.26 (1.00–1.59) 30 38
Stroke 1.41 (1.07–1.85) 21 29
Pulmonary embolism 2.13 (1.39–3.25) 8 16
Colorectal cancer 0.63 (0.43–0.92) 16 10
Endometrial cancer 0.83 (0.47–1.47) 6 5
Hip fracture 0.66 (0.45–0.98) 15 10
Death due to causes other than above 0.92 (0.74–1.14) 40 37
Global Index[lower-alpha 5] 1.15 (1.03–1.28) 151 170
Deep vein thrombosis[lower-alpha 6] 2.07 (1.49–2.87) 13 26
Vertebral fractures[lower-alpha 6] 0.66 (0.44–0.98) 15 9
Other osteoporotic fractures[lower-alpha 6] 0.77 (0.69–0.86) 170 131
Footnotes and sources
Footnotes:
  1. Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.
  2. Non-fatal myocardial infarction.
  3. Coronary heart disease death.
  4. Includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer.
  5. A subset of the events was combined in a "global index", defined as the earliest occurrence of coronary heart disease events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes.
  6. 6.0 6.1 6.2 Not included in Global Index.
Sources: [1][2]
Template documentation

References

  1. Warner Chilcott (March 2005). "ESTRACE TABLETS, (estradiol tablets, USP)" (PDF). fda.gov. Retrieved 27 November 2016.
  2. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (July 2002). "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial". JAMA. 288 (3): 321–33. doi:10.1001/jama.288.3.321. PMID 12117397.